Project Grant R01HL170905
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $324,000 to the Rector & Visitors of the University of Virginia (UVA) to investigate the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for treating women with angina, non-obstructive coronary artery disease (ANOCA), and coronary microvascular disease (CMD). The 5-year project aims to: 1) test the efficacy of SGLT2i in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $599,921 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of METTL3, an RNA modification enzyme, in diabetic cardiomyopathy and the cardiac benefits of exercise in diabetes. The research aims to determine how METTL3 regulates the pathophysiology of diabetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $834,531 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), a risk factor for atherosclerotic cardiovascular disease. The research aims to investigate vascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
This federal Project Grant award of $771,902 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to examine the effects of HIV-associated extracellular vesicles (EVs) containing the protein NEF on macrophage heterogeneity and function, and their contribution to the formation of high-risk atherosclerotic plaques in people living with HIV. The research aims to identify novel mechanisms and therapeutic targets related to impaired...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
The federal Project Grant award of $100,050.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the potential role of cardiometabolic drugs, such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2I), as well as the repurposing of metformin and bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research...